CSTL · Castle Biosciences, Inc.
$33.08
-0.33% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-36.2
Dividend yield
0.0%
Beta
0.94
Avg volume
0M
Employees
1K
Daily Change %
-0.33%
5 Days Change
2.84%
10 Days Change
-0.09%
30 Days Change
-6.00%
60 Days Change
-5.49%
Month to Day Change
-6.17%
Year to Day Change
-14.96%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CSTL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-03
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | BTIG | Maintains | Buy | $40.00 → $44.00 |
| 2026-06-25 | Roth Capital | Initiates | Buy | $0.00 → $40.00 |
| 2026-05-13 | BTIG | Maintains | Buy | $50.00 → $40.00 |
| 2026-05-07 | Baird | Maintains | Outperform | $44.00 → $43.00 |
| 2026-04-20 | Canaccord Genuity | Maintains | Buy | $50.00 → $40.00 |
| 2026-02-27 | Baird | Maintains | Outperform | $41.00 → $44.00 |
| 2026-01-26 | Guggenheim | Maintains | Buy | $43.00 → $47.00 |
| 2026-01-12 | Lake Street | Maintains | Buy | $35.00 → $52.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 1.8% below the 50-day MA ($33.69).
- bullish: Price vs 200-day MA: Trading 15.6% above the 200-day MA ($28.62).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.13) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($18.15) and high ($43.04).
CSTL Price Chart
Loading chart for CSTL…
Fundamentals
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.